Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Teva Signs Development Deal With OncoGenex

By Drug Discovery Trends Editor | December 21, 2009

NEW YORK (AP) – Teva Pharmaceutical Industries Ltd. said it entered a global licensing and collaboration agreement for OncoGenex Pharmaceuticals Inc.’s potential cancer treatment OGX-011 for $60 million, including an equity investment.

However, shares of OncoGenex tumbled following the announcement as investors scrutinized the terms and payment structure of the agreement.

Under the deal, OncoGenex will receive $60 million up front, including a $10 million equity investment valuing its stock at $37.38 per share, which represents a 26 percent premium to its closing price of $29.65 on Friday. The upfront payment includes $20 million in cash and $30 million in a prepayment for development costs.

OncoGenex will be eligible to receive up to $370 million in milestone and other payments, along with royalties.

However, OncoGenex has to pay its partner, Isis Pharmaceuticals Inc., $10 million upfront as part of the deal. Isis, based in Carlsbad, Calif., co-discovered OGX-011. Isis said it will also receive 30 percent of the milestone and other payments up to $370 million, and is also eligible for between 5.5 percent and 7 percent of royalties on all sales of OGX-011.

OncoGenex, based in Bothell, Wash., retains an option to co-promote OGX-011 in the U.S. and Canada. The drug candidate is expected to move into late-stage development as a potential prostate and lung cancer treatment in 2010 and 2011. The drug is expected to be used an additional therapy to enhance the effectiveness of chemotherapy.

OncoGenex shares plunged $7.62, or 25.7 percent, to $22.03 in midday trading. The stock has ranged from $2.87 to $42.99 over the past year.

Teva shares rose $1.37, or 2.6 percent, to $54.28. Shares of Isis rose 85 cents to a new year high of $50.45.

Date: December 21, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE